Bloating relief? tiny trial tests antibiotic for stomach paralysis
NCT ID NCT04254549
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small Phase 2 trial tested whether the antibiotic rifaximin could reduce bloating in people with diabetic gastroparesis, a condition where the stomach empties slowly. Only 5 participants were enrolled before the study was terminated early. The main goal was to measure changes in bloating using detailed questionnaires.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rifaximin
- What this could lead to
- If it works, this could point toward a treatment for bloating in diabetic gastroparesis.
- What could go wrong
- This trial was terminated early and enrolled only 5 people, so results are very limited. It may not show clear benefit or apply to larger groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?